MIS416 is a microparticulate formulation derived from propionibacterium acnes cell wall skeletons with intrinsic adjuvant activity. Conjugates of MIS416-SS-peptide containing a disulfide linkage facilitate the cytoplasmic delivery and release of peptides in antigen-presenting cells (APCs). We hypothesized that MIS416-siRNA (small interfering RNA) conjugates, containing a disulfide linkage between MIS416 and the siRNA, would allow cytoplasmic release of siRNA in APCs. MIS416-SS-siStat3 conjugates added to cell culture medium of monolayers of DCs in culture flasks successfully targeted Stat3 mRNA in DCs in vitro without transfection, downregulating Stat3 mRNA and protein levels. These results suggest that MIS416-SS-siRNA conjugates can be used as a novel siRNA delivery system for the knockdown of mRNA levels in APCs.
Get full access to this article
View all access options for this article.
References
1.
Palanca-WesselsMC, BoothGC, ConvertineAJ, LundyBB, BerguigGY, PressMF, StaytonPS and PressOW. (2016). Antibody targeting facilitates effective intratumoral siRNA nanoparticle delivery to HER2-overexpressing cancer cells. Oncotarget, 7:9561–9575.
2.
GuS, HuZ, NgamcherdtrakulW, CastroDJ, MorryJ, RedaMM, GrayJW and YantaseeW. (2016). Therapeutic siRNA for drug-resistant HER2-positive breast cancer. Oncotarget, 7:14727–14741.
3.
MaoM, ChenJ, LiX and WuZ. (2015). siRNA-TMEM98 inhibits the invasion and migration of lung cancer cells. Int J Clin Exp Pathol, 8:15661–15669.
4.
MaduriS. (2015). Applicability of RNA interference in cancer therapy: current status. Indian J Cancer, 52:11–21.
5.
DraghiciB and IliesMA. (2015). Synthetic nucleic acid delivery systems: present and perspectives. J Med Chem, 58:4091–4130.
6.
BrennerMK, GottschalkS, LeenAM and VeraJF. (2013). Is cancer gene therapy an empty suit?. Lancet Oncol, 14:e447–e456.
7.
WittrupA and LiebermanJ. (2015). Knocking down disease: a progress report on siRNA therapeutics. Nat Rev Genet, 16:543–552.
8.
DominskaM and DykxhoornDM. (2010). Breaking down the barriers: siRNA delivery and endosome escape. J Cell Sci, 123(Pt 8):1183–1189.
GirvanRC, KnightDA, O'loughlinCJ, HaymanCM, HermansIF and WebsterGA. (2011). MIS416, a non-toxic microparticle adjuvant derived from Propionibacterium acnes comprising immunostimulatory muramyl dipeptide and bacterial DNA promotes cross-priming and Th1 immunity. Vaccine, 29:545–557.
11.
BoćkoD, KosmaczewskaA, CiszakL, TeodorowskaR and FrydeckaI. (2002). CD28 costimulatory molecule–expression, structure and function. Arch Immunol Ther Exp (Warsz), 50:169–177.
12.
FerrandJ and FerreroRL. (2013). Recognition of extracellular bacteria by NLRs and its role in the development of adaptive immunity. Front Immunol, 4:344.
13.
HeX, JiaH, JingZ and LiuD. (2013). Recognition of pathogen-associated nucleic acids by endosomal nucleic acid-sensing toll-like receptors. Acta Biochim Biophys Sin Shanghai, 45:241–258.
14.
KhanANH, KolomeyevskayaN, SingelKL, GrimmMJ, MoysichKB, DaudiS, GrzankowskiKS, LeleS, YlaganL, et al. (2015). Targeting myeloid cells in the tumor microenvironment enhances vaccine efficacy in murine epithelial ovarian cancer. Oncotarget, 6:11310–11326.
15.
MaininiF, LarsenDS, WebsterGA, YoungSL and EcclesMR. (2015). Bridging small molecules to modified bacterial microparticles using a disulphide linkage: MIS416 as a cargo delivery system. PLoS One, 10:e0145403.
16.
PradhanP, QinH, LeleuxD, GwakIS, KwakLW, RoyK, RoyK. (2014). The effect of combined IL10 siRNA and CpG ODN as pathogen-mimicking microparticles on Th1/Th2 cytokine balance in dendritic cells and protective immunity against B cell lymphoma. Biomaterials, 35:5491–5504.
17.
KhansarizadehM, MokhtarzadehA, RashediniaM, TaghdisiSM, LariP, AbnousKH and RamezaniM. (2016). Identification of possible cytotoxicity mechanism of polyethylenimine by proteomics analysis. Hum Exp Toxicol, 35:377–387.
18.
MorimotoK, NishikawaM, KawakamiS, TaghdisiSM, LariP, AbnousKH, RamezaniM, HashidaM. (2003). Molecular weight-dependent gene transfection activity of unmodified and galactosylated polyethyleneimine on hepatoma cells and mouse liver. Mol Ther, 7:254–261.
19.
SongL, TurksonJ, KarrasJG, JoveR and HauraEB. (2003). Activation of Stat3 by receptor tyrosine kinases and cytokines regulates survival in human non-small cell carcinoma cells. Oncogene, 22:4150–4165.
20.
YuH, KortylewskiM and PardollD. (2007). Crosstalk between cancer and immune cells: role of STAT3 in the tumour microenvironment. Nat Rev Immunol, 7:41–51.
21.
KortylewskiM, KujawskiM, WangT, WeiS, ZhangS, Pilon-ThomasS, NiuG, KayH, MuléJ, et al. (2005). Inhibiting Stat3 signaling in the hematopoietic system elicits multicomponent antitumor immunity. Nat Med, 11:1314–1321.
22.
WangT, NiuG, KortylewskiM, BurdelyaL, ShainK, ZhangS, BhattacharyaR, GabrilovichD, HellerR, et al. (2004). Regulation of the innate and adaptive immune responses by Stat-3 signaling in tumor cells. Nat Med, 10:48–54.
23.
RébéC, VégranF, BergerH and GhiringhelliF. (2013). STAT3 activation: a key factor in tumor immunoescape. JAK-STAT, 2:e23010.
24.
SanseverinoI, PurificatoC, VaranoB, ContiL, GessaniS and GauzziMC. (2014). STAT3-silenced human dendritic cells have an enhanced ability to prime IFNγ production by both αβ and γδ T lymphocytes. Immunobiology, 219:503–511.
25.
MelilloJA, SongL, BhagatG, BlazquezAB, PlumleeCR, LeeC, BerinC, ReizisB and SchindlerC. (2010). Dendritic cell (DC)-specific targeting reveals Stat3 as a negative regulator of DC function. J Immunol, 184:2638–2645.
26.
NefedovaY, HuangM, KusmartsevS, BhattacharyaR, ChengP, SalupR, JoveR and GabrilovichD. (2004). Hyperactivation of STAT3 is involved in abnormal differentiation of dendritic cells in cancer. J Immunol, 172:464–474.
27.
AlshamsanA, HaddadiA, HamdyS, SamuelJ, El-KadiAO, UludağH and LavasanifarA. (2010). STAT3 silencing in dendritic cells by siRNA polyplexes encapsulated in PLGA nanoparticles for the modulation of anticancer immune response. Mol Pharm, 7:1643–1654.
28.
ChenQ, WangH, LiuY, SongY, LaiL, HanQ, CaoX and WangQ. (2012). Inducible microRNA-223 down-regulation promotes TLR-triggered IL-6 and IL-1β production in macrophages by targeting STAT3. PLoS One, 7:e42971.
29.
Jadidi-NiaraghF, AtyabiF, RastegariA, KheshtchinN, ArabS, HassanniaH, AjamiM, MirsaneiZ, HabibiS, et al. (2017). CD73 specific siRNA loaded chitosan lactate nanoparticles potentiate the antitumor effect of a dendritic cell vaccine in 4T1 breast cancer bearing mice. J Control Release, 246:46–59.
30.
DongZ, ChenY, PengY, WangF, YangZ, HuangG, ChenY, YuanZ, CaoT and PengY. (2017). Concurrent CCR7 overexpression and RelB knockdown in immature dendritic cells induces immune tolerance and improves skin-graft survival in a murine model. Cell Physiol Biochem, 42:455–468.
31.
KeN, SuA, HuangW, SzatmaryP and ZhangZ. (2016). Regulating the expression of CD80/CD86 on dendritic cells to induce immune tolerance after xeno-islet transplantation. Immunobiology, 221:803–812.
32.
AhnY-H, HongS-O, KimJH, NohKH, SongKH, LeeYH, JeonJH, KimDW, SeoJH and KimTW. (2015). The siRNA cocktail targeting interleukin 10 receptor and transforming growth factor-β receptor on dendritic cells potentiates tumour antigen-specific CD8(+) T cell immunity. Clin Exp Immunol, 181:164–178.
33.
WangT, JiangQ, ChanC, GorskiKS, McCaddenE, KardianD, PardollD and WhartenbyKA. (2009). Inhibition of activation-induced death of dendritic cells and enhancement of vaccine efficacy via blockade of MINOR. Blood, 113:2906–2913.
34.
Iwata-KajiharaT, SumimotoH, KawamuraN, UedaR, TakahashiT, MizuguchiH, MiyagishiM, TakedaK and KawakamiY. (2011). Enhanced cancer immunotherapy using STAT3-depleted dendritic cells with high Th1-inducing ability and resistance to cancer cell-derived inhibitory factors. J Immunol, 187:27–36.
35.
AssiH, EspinosaJ, SurpriseS, SofroniewM, DohertyR, ZamlerD, LowensteinPR and CastroMG. (2014). Assessing the role of STAT3 in DC differentiation and autologous DC immunotherapy in mouse models of GBM. PLoS One, 9:e96318.
36.
ZhangQ, HossainDMS, DuttaguptaP, MoreiraD, ZhaoX, WonH, BuettnerR, NechaevS, MajkaM, et al. (2016). Serum-resistant CpG-STAT3 decoy for targeting survival and immune checkpoint signaling in acute myeloid leukemia. Blood, 127:1687–1700.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
